krystal biotech vyjuvek

Krystal, Vyjuvek and Jefferies

Krystal Biotech initiated at buy at Jefferies on Vyjuvek, gene delivery tech

Jefferies has initiated Krystal Biotech at buy citing growth in sales of Vyjuvek (beremagene geperpavec), a gene therapy for a rare skin condition, as well as its in-house gene delivery technology. The investment firm has a $245 price target (~40% upside based on March 4 close).

MarketWatch · 6d

Krystal Biotech Gets CHMP Backing for Vyjuvek Approval

Krystal Biotech said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Vyjuvek topical gene therapy for certain patients with the rare genetic skin disorder dystrophic epidermolysis bullosa, or DEB.

Markets Insider · 1d

Krystal Biotech initiated with a Buy at Jefferies

Jefferies analyst Roger Song initiated coverage of Krystal Biotech (KRYS) with a Buy rating and $245 price target Krystal is a commercial

Fintel on MSN · 1d

Jefferies Initiates Coverage of Krystal Biotech (KRYS) with Buy Recommendation

Fintel reports that on March 5, 2025, Jefferies initiated coverage of Krystal Biotech (NasdaqGS:KRYS) with a Buy recommendation. Analyst Price Forecast Suggests 23.09% Upside As of March 4, 2025, the average one-year price target for Krystal Biotech is $215.

Zacks Investment Research on MSN3d

KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug

Krystal Biotech KRYS announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

Krystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA’s) announcement that its Committee for Medicinal ...

PMLive3d

Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa

The European Medicines Agency’s (EMA) human medicines committee has recommended Krystal Biotech’s Vyjuvek (beremagene ...

Nasdaq6d

Krystal Biotech, Inc. Welcomes Positive EMA Recommendation for VYJUVEK® Approval in Dystrophic Epidermolysis Bullosa

Krystal Biotech, Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive recommendation for VYJUVEK® (beremagene geperpavec-svdt ...

13d

Krystal Biotech Soars As Q4 Earnings Put Blockbuster Commercialization In Focus

Krystal Biotech's VYJUVEK sees strong growth with $1B+ 2025 sales forecast. Check out why I rate KRYS as a Strong Buy and my ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results